理解顺铂诱导毒性的进展:分子机制与保护策略》。

IF 4.3 3区 医学 Q1 PHARMACOLOGY & PHARMACY European Journal of Pharmaceutical Sciences Pub Date : 2024-10-17 DOI:10.1016/j.ejps.2024.106939
Elsayed A. Elmorsy , Sameh Saber , Rabab S. Hamad , Mustafa Ahmed Abdel-Reheim , Attalla F. El-kott , Mohammed A. AlShehri , Kareem Morsy , Salama A. Salama , Mahmoud E. Youssef
{"title":"理解顺铂诱导毒性的进展:分子机制与保护策略》。","authors":"Elsayed A. Elmorsy ,&nbsp;Sameh Saber ,&nbsp;Rabab S. Hamad ,&nbsp;Mustafa Ahmed Abdel-Reheim ,&nbsp;Attalla F. El-kott ,&nbsp;Mohammed A. AlShehri ,&nbsp;Kareem Morsy ,&nbsp;Salama A. Salama ,&nbsp;Mahmoud E. Youssef","doi":"10.1016/j.ejps.2024.106939","DOIUrl":null,"url":null,"abstract":"<div><div>Cisplatin, a widely used chemotherapeutic agent, has proven efficacy against various malignancies. However, its clinical utility is hampered by its dose-limiting toxicities, including nephrotoxicity, ototoxicity, neurotoxicity, and myelosuppression. This review aims to provide a comprehensive overview of cisplatin toxicity, encompassing its underlying mechanisms, risk factors, and emerging therapeutic strategies. The mechanisms of cisplatin toxicity are multifactorial and involve oxidative stress, inflammation, DNA damage, and cellular apoptosis. Various risk factors contribute to the interindividual variability in susceptibility to cisplatin toxicity. The risk of developing cisplatin-induced toxicity could be related to pre-existing conditions, including kidney disease, hearing impairment, neuropathy, impaired liver function, and other comorbidities. Additionally, this review highlights the emerging therapeutic strategies that could be applied to minimize cisplatin-induced toxicities and aid in optimizing cisplatin treatment regimens, improving patient outcomes, and enhancing the overall quality of cancer care.</div></div>","PeriodicalId":12018,"journal":{"name":"European Journal of Pharmaceutical Sciences","volume":"203 ","pages":"Article 106939"},"PeriodicalIF":4.3000,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Advances in understanding cisplatin-induced toxicity: Molecular mechanisms and protective strategies\",\"authors\":\"Elsayed A. Elmorsy ,&nbsp;Sameh Saber ,&nbsp;Rabab S. Hamad ,&nbsp;Mustafa Ahmed Abdel-Reheim ,&nbsp;Attalla F. El-kott ,&nbsp;Mohammed A. AlShehri ,&nbsp;Kareem Morsy ,&nbsp;Salama A. Salama ,&nbsp;Mahmoud E. Youssef\",\"doi\":\"10.1016/j.ejps.2024.106939\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Cisplatin, a widely used chemotherapeutic agent, has proven efficacy against various malignancies. However, its clinical utility is hampered by its dose-limiting toxicities, including nephrotoxicity, ototoxicity, neurotoxicity, and myelosuppression. This review aims to provide a comprehensive overview of cisplatin toxicity, encompassing its underlying mechanisms, risk factors, and emerging therapeutic strategies. The mechanisms of cisplatin toxicity are multifactorial and involve oxidative stress, inflammation, DNA damage, and cellular apoptosis. Various risk factors contribute to the interindividual variability in susceptibility to cisplatin toxicity. The risk of developing cisplatin-induced toxicity could be related to pre-existing conditions, including kidney disease, hearing impairment, neuropathy, impaired liver function, and other comorbidities. Additionally, this review highlights the emerging therapeutic strategies that could be applied to minimize cisplatin-induced toxicities and aid in optimizing cisplatin treatment regimens, improving patient outcomes, and enhancing the overall quality of cancer care.</div></div>\",\"PeriodicalId\":12018,\"journal\":{\"name\":\"European Journal of Pharmaceutical Sciences\",\"volume\":\"203 \",\"pages\":\"Article 106939\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-10-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Pharmaceutical Sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0928098724002525\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Pharmaceutical Sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0928098724002525","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

顺铂是一种广泛使用的化疗药物,对各种恶性肿瘤的疗效已得到证实。然而,其剂量限制性毒性(包括肾毒性、耳毒性、神经毒性和骨髓抑制)阻碍了其临床应用。本综述旨在全面概述顺铂毒性,包括其潜在机制、风险因素和新兴治疗策略。顺铂毒性的机制是多因素的,涉及氧化应激、炎症、DNA 损伤和细胞凋亡。各种风险因素导致了顺铂毒性易感性的个体差异。发生顺铂诱导毒性的风险可能与原有疾病有关,包括肾脏疾病、听力损伤、神经病变、肝功能受损和其他合并症。此外,本综述还重点介绍了可用于尽量减少顺铂诱导毒性的新兴治疗策略,这些策略有助于优化顺铂治疗方案、改善患者预后和提高癌症护理的整体质量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Advances in understanding cisplatin-induced toxicity: Molecular mechanisms and protective strategies
Cisplatin, a widely used chemotherapeutic agent, has proven efficacy against various malignancies. However, its clinical utility is hampered by its dose-limiting toxicities, including nephrotoxicity, ototoxicity, neurotoxicity, and myelosuppression. This review aims to provide a comprehensive overview of cisplatin toxicity, encompassing its underlying mechanisms, risk factors, and emerging therapeutic strategies. The mechanisms of cisplatin toxicity are multifactorial and involve oxidative stress, inflammation, DNA damage, and cellular apoptosis. Various risk factors contribute to the interindividual variability in susceptibility to cisplatin toxicity. The risk of developing cisplatin-induced toxicity could be related to pre-existing conditions, including kidney disease, hearing impairment, neuropathy, impaired liver function, and other comorbidities. Additionally, this review highlights the emerging therapeutic strategies that could be applied to minimize cisplatin-induced toxicities and aid in optimizing cisplatin treatment regimens, improving patient outcomes, and enhancing the overall quality of cancer care.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
9.60
自引率
2.20%
发文量
248
审稿时长
50 days
期刊介绍: The journal publishes research articles, review articles and scientific commentaries on all aspects of the pharmaceutical sciences with emphasis on conceptual novelty and scientific quality. The Editors welcome articles in this multidisciplinary field, with a focus on topics relevant for drug discovery and development. More specifically, the Journal publishes reports on medicinal chemistry, pharmacology, drug absorption and metabolism, pharmacokinetics and pharmacodynamics, pharmaceutical and biomedical analysis, drug delivery (including gene delivery), drug targeting, pharmaceutical technology, pharmaceutical biotechnology and clinical drug evaluation. The journal will typically not give priority to manuscripts focusing primarily on organic synthesis, natural products, adaptation of analytical approaches, or discussions pertaining to drug policy making. Scientific commentaries and review articles are generally by invitation only or by consent of the Editors. Proceedings of scientific meetings may be published as special issues or supplements to the Journal.
期刊最新文献
Automated Extrusion-Based Dispensing: Personalized Dosing and Quality Control of Clopidogrel Tablets for Pediatric Care. Multiphysics Simulation of Liposome Release from Hydrogels for Cavity Filling Following Patient-Specific Breast Tumor Surgery. Towards optimization of dexamethasone therapy in the maintenance phase of pediatric acute lymphoblastic leukemia: a population pharmacokinetic and pharmacodynamic study of dexamethasone and metabolite. Disassembly and in vitro cell compatibility of α-lactalbumin particulates under physiologically relevant conditions Exploration of solubilisation effects facilitated by the combination of Soluplus® with ionic surfactants.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1